Logo for Outlook Therapeutics Inc

Outlook Therapeutics Investor Relations Material

Latest events

Logo for Outlook Therapeutics Inc

Study Update

Outlook Therapeutics
Logo for Outlook Therapeutics

Q1 2025

14 Feb, 2025
Logo for Outlook Therapeutics

Study Update

4 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Outlook Therapeutics Inc

Access all reports
Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and launching innovative treatments for ocular diseases. The company is currently working on ONS-5010 / LYTENAVA™ (bevacizumab-vikg), aiming to make it the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The company is headquartered in Iselin, New Jersey, and its shares are listed on the Nasdaq.